-
Something wrong with this record ?
A pilot study to monitor Graves' ophthalmopathy with a combination of pattern-reversal and motion-onset visual evoked potentials
J. Szanyi, J. Kremlacek, Z. Kubova, J. Langrova, M. Kuba,
Language English Country United States
Document type Clinical Trial, Journal Article
NLK
Medline Complete (EBSCOhost)
from 2012-01-01 to 1 year ago
Wiley Online Library (archiv)
from 1996-01-01 to 2012-12-31
PubMed
22811284
DOI
10.1002/jca.21243
Knihovny.cz E-resources
- MeSH
- Administration, Oral MeSH
- Decompression, Surgical MeSH
- Adult MeSH
- Graves Ophthalmopathy drug therapy physiopathology surgery therapy MeSH
- Immunoglobulins, Intravenous therapeutic use MeSH
- Infusions, Intravenous MeSH
- Combined Modality Therapy MeSH
- Middle Aged MeSH
- Humans MeSH
- Methylprednisolone administration & dosage therapeutic use MeSH
- Drug Monitoring methods MeSH
- Pilot Projects MeSH
- Prednisone administration & dosage therapeutic use MeSH
- Pulse Therapy, Drug MeSH
- Reaction Time MeSH
- Blood Component Removal MeSH
- Treatment Outcome MeSH
- Visual Acuity drug effects physiology MeSH
- Evoked Potentials, Visual * physiology MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Clinical Trial MeSH
OBJECTIVE: The aim of this pilot study was to evaluate the efficacy of visual evoked potentials (VEPs) in the monitoring of visual function during a high-dose intravenous steroid pulse therapy and apheresis treatment of severe Graves' ophthalmopathy (GO). PATIENTS AND RESEARCH DESIGN: Nine patients with severe and active GO were treated with high-dose methylprednisolone (1 g day(-1) three times within 1 week, then 0.5 g day(-1) seven times for 2 weeks) combined with plasma filtration (twice a week in weeks 1, 2, 4, 7, and 10). Pattern-reversal and motion-onset VEPs were examined three times, pretreatment, after steroid pulses, and after the last apheresis. RESULTS: After 10 steroid pulses, the visual acuity was significantly better and the pattern-reversal VEP amplitudes (element size of only 20') had a similar trend for improvement. However, this effect disappeared after 7 weeks when only apheresis treatment was performed. No significant changes in the latencies of any of the tested VEP variants were found in relationship to the treatment. CONCLUSION: Only the observed large intraindividual variability of the VEP parameters between repeated examinations of patients with the shortest duration of GO might be recognized as a marker for functional changes of the visual pathway due to GO. Although this pilot study cannot provide a definite view on the usefulness of the extended set of VEPs in objective monitoring of GO, it seems that the steroid pulse therapy effect is detectable in contrast to the lack of influence by apheresis on the electrophysiological parameters tested.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc13024377
- 003
- CZ-PrNML
- 005
- 20130710112517.0
- 007
- ta
- 008
- 130703s2012 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1002/jca.21243 $2 doi
- 035 __
- $a (PubMed)22811284
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Szanyi, Jana $u Department of Pathophysiology, Charles University, Hradec Králové, Czech Republic. szanyi@lfhk.cuni.cz
- 245 12
- $a A pilot study to monitor Graves' ophthalmopathy with a combination of pattern-reversal and motion-onset visual evoked potentials / $c J. Szanyi, J. Kremlacek, Z. Kubova, J. Langrova, M. Kuba,
- 520 9_
- $a OBJECTIVE: The aim of this pilot study was to evaluate the efficacy of visual evoked potentials (VEPs) in the monitoring of visual function during a high-dose intravenous steroid pulse therapy and apheresis treatment of severe Graves' ophthalmopathy (GO). PATIENTS AND RESEARCH DESIGN: Nine patients with severe and active GO were treated with high-dose methylprednisolone (1 g day(-1) three times within 1 week, then 0.5 g day(-1) seven times for 2 weeks) combined with plasma filtration (twice a week in weeks 1, 2, 4, 7, and 10). Pattern-reversal and motion-onset VEPs were examined three times, pretreatment, after steroid pulses, and after the last apheresis. RESULTS: After 10 steroid pulses, the visual acuity was significantly better and the pattern-reversal VEP amplitudes (element size of only 20') had a similar trend for improvement. However, this effect disappeared after 7 weeks when only apheresis treatment was performed. No significant changes in the latencies of any of the tested VEP variants were found in relationship to the treatment. CONCLUSION: Only the observed large intraindividual variability of the VEP parameters between repeated examinations of patients with the shortest duration of GO might be recognized as a marker for functional changes of the visual pathway due to GO. Although this pilot study cannot provide a definite view on the usefulness of the extended set of VEPs in objective monitoring of GO, it seems that the steroid pulse therapy effect is detectable in contrast to the lack of influence by apheresis on the electrophysiological parameters tested.
- 650 _2
- $a aplikace orální $7 D000284
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a separace krevních složek $7 D001781
- 650 _2
- $a kombinovaná terapie $7 D003131
- 650 _2
- $a chirurgická dekomprese $7 D019299
- 650 _2
- $a monitorování léčiv $x metody $7 D016903
- 650 12
- $a zrakové evokované potenciály $x fyziologie $7 D005074
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a Gravesova oftalmopatie $x farmakoterapie $x patofyziologie $x chirurgie $x terapie $7 D049970
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a intravenózní imunoglobuliny $x terapeutické užití $7 D016756
- 650 _2
- $a intravenózní infuze $7 D007262
- 650 _2
- $a methylprednisolon $x aplikace a dávkování $x terapeutické užití $7 D008775
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a pilotní projekty $7 D010865
- 650 _2
- $a prednison $x aplikace a dávkování $x terapeutické užití $7 D011241
- 650 _2
- $a pulzní dávkování léků $7 D020551
- 650 _2
- $a reakční čas $7 D011930
- 650 _2
- $a výsledek terapie $7 D016896
- 650 _2
- $a zraková ostrost $x účinky léků $x fyziologie $7 D014792
- 655 _2
- $a klinické zkoušky $7 D016430
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Kremlacek, Jan $u -
- 700 1_
- $a Kubova, Zuzana $u -
- 700 1_
- $a Langrova, Jana $u -
- 700 1_
- $a Kuba, Miroslav $u -
- 773 0_
- $w MED00180287 $t Journal of clinical apheresis $x 1098-1101 $g Roč. 27, č. 6 (2012), s. 295-301
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/22811284 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20130703 $b ABA008
- 991 __
- $a 20130710112941 $b ABA008
- 999 __
- $a ok $b bmc $g 988057 $s 822757
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2012 $b 27 $c 6 $d 295-301 $i 1098-1101 $m Journal of clinical apheresis $n J Clin Apher $x MED00180287
- LZP __
- $a Pubmed-20130703